Lenalidomide Zentiva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s activity, leading to the ubiquitination and degradation of transcription factors Ikaros and Aiolos. The result is reduced tumor cell proliferation, inhibition of new blood‑vessel formation, and enhanced immune‑mediated tumor killing.

The exact dose of Lenalidomide Zentiva is individualized by the prescribing physician based on the specific indication, disease stage, patient’s renal function, and other clinical factors. No universal dosing schedule is provided here; clinicians set the regimen according to approved guidelines and patient needs.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It should not be used by breastfeeding mothers, as it may be excreted in milk and pose risks to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Lenalidomide shares the same class (immunomodulatory agents) as thalidomide and pomalidomide but generally offers a more favorable safety profile, especially regarding peripheral neuropathy. It is more potent than thalidomide and is often preferred for multiple myeloma and del(5q) MDS, while pomalidomide may be reserved for later‑line therapy after lenalidomide failure.

Store Lenalidomide Zentiva tablets at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Lenalidomide Zentiva is taken orally as a tablet, usually with or without food as directed by the prescriber. Patients should swallow the tablet whole with water and follow the dosing schedule provided by their healthcare professional.

The most serious risks include venous thromboembolism (blood clots), severe neutropenia or thrombocytopenia (dangerously low white‑blood‑cell or platelet counts), and the possible development of secondary primary malignancies. Patients should be monitored closely for signs of infection, bleeding, or unexplained pain and report any concerns promptly.

Lenalidomide Zentiva should not be used by pregnant women, individuals with severe renal impairment without dose adjustment, patients with uncontrolled infections, or anyone with known hypersensitivity to lenalidomide or its excipients. Clinicians must evaluate each patient’s medical history before initiating therapy.